Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry

Michael Beck¹, Uma Ramaswami²*, Elizabeth Hernberg-Ståhl³, Derralynn A. Hughes², Christoph Kampmann⁴, Atul B. Mehta⁵, Kathleen Nicholls⁶, Dau-Ming Niu⁷, Guillem Pintos-Morell⁸, Ricardo Reisin⁹, Michael L. West¹⁰, Jörn Schenk¹¹, Christina Anagnostopoulou¹¹, Jaco Botha¹¹ and Roberto Giugliani¹²

Abstract

Background: Patient registries provide long-term, real-world evidence that aids the understanding of the natural history and progression of disease, and the effects of treatment on large patient populations with rare diseases. The year 2021 marks the 20th anniversary of the Fabry Outcome Survey (FOS), an international, multicenter, observational registry (NCT03289065). The primary aims of FOS are to broaden the understanding of Fabry disease (FD), an X-linked lysosomal storage disorder, and to improve the clinical management of affected patients. Here, we review the history of FOS and the analyses and publications disseminated from the registry, and we discuss the contributions FOS studies have made in understanding FD.

Results: FOS was initiated in April 2001 and, as of January 2021, 4484 patients with a confirmed diagnosis and patient informed consent have been enrolled from 144 centers across 26 countries. Data from FOS have been published in nearly 60 manuscripts on a wide variety of topics relevant to FD. Analyses of FOS data have investigated the long-term effectiveness and safety of enzyme replacement therapy (ERT) with agalsidase alfa and its effects on morbidity and mortality, as well as the benefits of prompt and early treatment with agalsidase alfa on the progression of cardiomyopathy and the decline in renal function associated with FD. Based on analyses of FOS data, ERT with agalsidase alfa has also been shown to improve additional signs and symptoms of FD experienced by patients. FOS data analyses have provided a better understanding of the natural history of FD and the specific populations of women, children, and the elderly, and have provided practical tools for the study of FD. FOS has also provided methodology and criteria for assessing disease severity which contributed to the continuous development of medical practice in FD and has largely improved our understanding of the challenges and needs of long-term data collection in rare diseases, aiding in future rare disease real-world evidence studies.

Conclusion: FOS over the last 20 years has substantially increased the scientific knowledge around improved patient management of FD and continues to expand our understanding of this rare disease.

Keywords: Agalsidase alfa, Enzyme replacement therapy, Fabry disease, Cardiovascular outcomes, Renal outcomes

© The Author(s) 2022. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

*Correspondence: uma.ramaswami@nhs.net

¹ Lysosomal Disorders Unit, Institute of Immunity and Transplantation, Royal Free London NHS Foundation Trust, University College London, London, UK

Full list of author information is available at the end of the article
allow the observation of large patient populations [1, 2]. Whereas randomized clinical trials are of short duration and test hypotheses, registries are of longer duration and generate hypotheses. Registry data, particularly for rare diseases, are increasingly important to government regulatory bodies and payers: the data extend the body of information that is available regarding long-term treatment effectiveness, the safety of medications, and health-related quality of life for patients. The year 2021 marked the 20th anniversary of the Fabry Outcome Survey (FOS), an international, multicenter, observational, physician-directed registry (NCT03289065) sponsored by Shire Human Genetic Therapies, Inc., a Takeda company [3, 4]. The primary aims of the FOS registry are to provide long-term data on the effectiveness and safety of enzyme replacement therapy with agalsidase alfa, broaden the understanding of Fabry disease (FD) and to improve the clinical management of affected patients [3, 4].

FD is an X-linked lysosomal storage disorder caused by more than 965 different mutations in the galactosidase alpha (GLA) gene that result in reduced or absent α-galactosidase A (α-Gal A) enzyme activity. This in turn leads to the accumulation of globotriaosylceramide (Gb3) [5–11]. Gb3 accumulation results in cell, tissue, and organ damage, leading to multisystem pathology typified by progressive renal and cardiovascular dysfunction; neuropathy; cerebrovascular events; ocular, dermatologic, gastrointestinal, and neuro-otologic manifestations; depression; and premature death [12–14]. Estimates of prevalence of FD range from approximately 1 in 117,000 to 1 in 37,000 live male births for classic FD and up to 1 in 1400 in some newborn screening projects when atypical FD variants are included [4, 15–18]. As an X-linked disease, FD had originally been considered as a disease mainly affecting male patients; however, female patients who are heterozygous for GLA mutations can also be affected, although onset is later and phenotypes are more variable [6, 13]. The variable clinical manifestation in female patients is attributed to many factors, including skewed X-inactivation; genetic variants; clonal expansion (which results in the secretion of the mature form of α-Gal A enzyme that is not readily taken up by cells); and somatic mosaicism resulting in an α-Gal A enzyme that is more susceptible to dephosphorylation in the plasma [19].

Enzyme replacement therapy (ERT) has been available for the treatment of FD since 2001 and is the standard of care [20]. Two ERT formulations are available currently [21–24]: agalsidase alfa (Replagal®), Shire Human Genetic Therapies AB, a member of the Takeda group of companies, Stockholm, Sweden, and first authorized 03 August 2001) [21, 22] and agalsidase beta (Fabrazyme®, Genzyme Corporation, a Sanofi company, Cambridge, MA, USA [23]; and Fabagel®, ISU Abxis Co, Ltd., Seoul, Republic of Korea [24]). Additionally, an α-Gal A pharmacological chaperone, migalastat (Galafold®, Amicus Therapeutics, Cranbury, NJ, USA) [25], can be used to treat certain patients with an amenable GLA mutation.

Patients with FD need life-long treatment that protects their organ function and improves survival. According to Wanner et al., “The aim of (Fabry disease) treatment is not only to slow or stop the progression of the disease and restore quality of life, but also to reverse Fabry pathology, minimizing the disease-associated morbidity and ultimately prolonging survival” [20]. There is a need for long-term effectiveness and safety data for FD treatments from a real-world setting. One way to obtain these data is by following patients undergoing routine treatment with available therapies as part of well-designed disease registries [1]. The inherent nature of long-term, observational patient registries makes them ideal for the assessment of treatment effectiveness in rare diseases in clinical practice [2]. Registries may include a more diverse range of patients regarding age, sex, disease severity, comorbidities, concomitant medications, or treatment than randomized clinical trials by having less strict inclusion criteria [1].

Considering the value of a registry in understanding disease and treatment management in the real world and the significance of having over 20 years of data from a long-term, rare disease registry, we review here the publications that have been developed on the basis of FOS registry data and discuss the contributions FOS has made to the scientific knowledge of FD.

**Design, history, and evolution of FOS**

FOS was established in April 2001 by TKT Europe-5S AB, under the direction of a European board and an executive committee, each comprising a panel of elected physicians. The objectives were to collect data on long-term clinical outcomes and safety, and to collect information on the rate of disease progression initially in European patients with FD who were untreated or treated with agalsidase alfa. From the outset, FOS data were used strictly for scientific aspects and regulatory requirements. The design of FOS has been described in detail in previous publications and has enabled the pooling of data from multiple centers to obtain sample sizes large enough for the evaluation of outcomes in treated and untreated patients [3, 4, 12, 26]. Patients or their caregivers provide consent for their data to be included via signed informed consent forms. Data are collected on a variety of key parameters, including—but not limited to—safety, cardiovascular, renal, cerebrovascular, and neurological evaluations, pain assessment, treatment, and quality of life (QoL). More recently (January 2017), information
on biomarkers has been added (e.g., globotriaosylsphingo-
gosine in urine and blood), and there are now separate questionnaires for pediatric patients. From 2005, a num-
ber of features designed to capture more comprehensive data were incorporated into FOS, including a focus on larger specialist centers (with $\geq 20$ patients) and the collection of data for a number of core FD-related variables covering both clinical and QoL-related parameters (in addition to comprehensive health checks) [2, 4].

On 26 March 2006, FOS was merged with the Fabry International Research Exchange (FIRE) database. FIRE, established in 2003 by Transkaryotic Therapies Inc, was a registry in non-European countries that was open to patients on ERT with a confirmed diagnosis of FD. The primary purpose of the FIRE registry was to document the natural history of FD, document changes in disease progression resulting from long-term ERT, provide a basis for developing treatment guidelines, and provide data that would lead to the development of better treatments.

The FOS protocol was subsequently amended on 29 June 2016 (Protocol Amendment 4) to become a disease registry so that any patient with FD, regardless of treatment, could be enrolled in FOS. This amendment enabled the collection of data from patients who switched treatments (e.g., from agalsidase alfa to agalsidase beta and/or migalastat) during the management of their disease.

FOS is directed by the FOS Steering Committee and representatives of the sponsor, which enable the smooth operation of the registry and ensure the scientific accuracy and appropriateness of all research concepts and proposals for data analyses and publications. The FOS Steering Committee includes FOS investigators who represent the geographical regions where the registry operates, and a patient organization delegate. The Steering Committee provides guidance on the overall direction of the registry by raising topics of scientific interest to be studied, endorsing data analyses and topics for publication, overseeing data quality and completeness, overseeing the functioning and activities of the Task Forces, and representing FOS at scientific meetings. FOS Task Forces were established to address specific topics. Task Force members are physicians or researchers with a particular expertise and interest in the relevant areas, such as nephrology, neurology, or cardiology, and they are responsible for all activities related to conducting and publishing in-depth analyses of FOS data in their field of interest.

Achievements of FOS

Since the first patient enrolled in FOS in 2001, the number of participating centers and countries has increased steadily, reaching 4484 patients with confirmed patient informed consent enrolled in FOS from 144 centers across 26 countries as of January 2021. In line with its original aims, FOS has contributed to the overall knowledge of FD, including a better understanding of the morbidity and mortality relating to the various organ systems affected; has provided methodology and criteria for grading disease severity; has defined the manifestations of FD in women, children, and the elderly; has improved patient management and led to earlier treatment; and has improved knowledge of FD genetic variants that result in late-onset versus classic forms of the disease.

As of January 2021, nearly 60 manuscripts utilizing data from FOS have been published on a wide variety of topics relevant to FD (Fig. 1). Instruments created from FOS include the FOS Mainz Severity Score Index (FOS-MSSI) [27, 28], the Fabry International Prognostic Index (FIP) [29], and the Fabry-specific Pediatric Health and Pain Questionnaire (FPHPQ) [30]. FIP is a prognostic severity scoring index that uses early symptoms of FD to differentiate patients with varying probabilities of experiencing a clinically significant event [29]. The FPHPQ is a quantitative assessment of patient-reported FD symptoms in children used to monitor disease progression and treatment effects [30]. The Mainz Severity Score Index (MSSI) [28] is used to score disease severity in FD. However, FOS uses a signs and symptoms checklist that produces dichotomous variables (i.e., yes or no), which are incompatible with scoring by the original MSSI [31]. The MSSI was therefore modified to accommodate FOS data, resulting in the FOS-MSSI [27, 28, 31]. The FOS-MSSI has sections relating to general, neurological, cardiovascular, and renal disease manifestations [31]. Signs and symptoms are weighted in accordance with the data collected in FOS, and the total score for disease severity obtained may be categorized as mild ($\leq 18$), moderate (19–38), or severe (>38) [6]. As such, the FOS-MSSI is used to give a description of the cumulative disease burden of FD (in contrast to the original MSSI) [6, 27, 28, 31].

**Fabry disease characteristics**

Analyses of FOS data have provided insight into the natural history of FD (classic and variants) and into the impact of treatment on disease progression in several affected organ systems and populations. FD affects neurologic, dermatologic, renal, cardiac, auditory, vascular, cerebrovascular, gastrointestinal, and ocular organ systems [12]. Signs and symptoms can include neuropathic pain, angiokeratomas, proteinuria, angina and dyspnea, gastrointestinal symptoms, cerebrovascular events, or tinnitus and vertigo. Many FOS publications raise awareness of the delays in receiving a diagnosis after the onset of symptoms. Among the first publications from FOS, an analysis of baseline (FOS entry) data for 366 patients
from 11 different countries illustrated the similar occurrence of FD symptoms in hemizygous male and heterozygous female patients [12]. The same analysis also showed substantial delays between symptom onset and diagnosis in male and female patients (13.7 and 16.6 years, respectively) [12]. Approximately 25% of FOS patients were misdiagnosed with rheumatological diseases, neuropsychological diseases, orthopedic diseases, and “others”, which included renal disease and coronary artery disease. A 2017 FOS analysis in 598 patients with FD found that the delay between symptom onset and diagnosis did not significantly improve between 2001–2006 and 2007–2013, although the median delay between diagnosis and treatment initiation decreased to approximately 1 year in children and 0.9 years in adults in the period 2007–2013 (Fig. 2) [32].

**Prognosis**

FOS data have been used to explore prognostic factors related to disease severity. The availability of data from FOS for a large number of patients (n = 1438) enabled the use of event-free survival for cardiovascular, renal, and neurologic endpoints to develop a validated prognostic scoring system for FD. This scoring system, called FIPI, can be used to differentiate patients based on the likelihood and timing of progression, and is therefore a useful aid for patient counseling and disease management [29]. An analysis exploring genotype–phenotype relationships found a highly significant correlation between age at entry into FOS and severity score, as well as between age at entry into FOS and the number of organs affected in male patients with missense mutations, suggestive of important associations between genotype and disease severity [33].

**Long-term effectiveness of ERT**

The long-term safety and effectiveness of ERT in pediatric and adult patients is also supported by data from FOS [34–40]. Overall, male and female patients had similar responses to agalsidase alfa, suggesting that there should be no difference in access to treatment if treatment criteria are met [41]. There is evidence, however, that there are sex disparities in initiating treatment with agalsidase alfa. This was illustrated by an analysis of FOS data for patients in Spain, which found that female patients with disease characteristics likely to benefit from ERT were less likely to receive treatment than male patients [42], an observation that was also seen in a German, non-FOS study of 261 female patients with FD [43]. These results also show discordance with consensus recommendations on when to
start treatment respective to each country, indicating that better adherence to treatment guidelines might lead to better outcomes for patients with FD in various countries.

**Benefits of prompt and early treatment with ERT**

FOS data have shown that not only does ERT benefit patients with FD by attenuating the progression of renal disease and cardiomyopathy, but also that prompt treatment reduces the risk of cardiovascular and renal events such as heart failure or dialysis, regardless of FD type (i.e., late-onset vs. classic FD) [44]. A FOS analysis that included 1374 patients (172 promptly treated, 1202 delayed; males 807, females 567) based on time from symptom onset and 2051 (1106 promptly treated, 1045 delayed; males 1130, females 921) based on time from diagnosis showed that in the overall population, prompt ERT initiation was associated with significant benefits in the reduction of cardiovascular events—both since symptom onset (hazard ratio [HR] = 0.62; p < 0.001) and since diagnosis (HR = 0.83; p < 0.003) [44]. These benefits occurred in both male and female patients with FD (female vs. male: symptom HR = 0.83, p = 0.018; diagnosis HR = 0.82, p = 0.003). Further, analysis by age at symptom onset showed that the beneficial effect of prompt initiation was more profound in patients ≤20 years of age at symptom onset [45]. An analysis of 560 male patients with FD showed the benefits of starting treatment in childhood or early adulthood. Starting ERT at age ≤18 years attenuated the progression of renal disease and cardiomyopathy, whereas patients receiving ERT for similar durations who started treatment as adults (>18 years) had statistically significant worsening in estimated glomerular filtration rate (eGFR) if started at age >18 years to ≤30 years, and in eGFR, proteinuria, and left ventricular mass index (LVMI) if started at age >30 years [45]. A different FOS analysis of LVMI and eGFR subgroups (LVMI, n = 560; eGFR, n = 1093) in male and female patients with FD showed that the risks of cardiovascular or renal events were significantly higher (both log-rank p < 0.0001) in patients with left ventricular hypertrophy (LVH) and in patients with eGFR < 90 mL/min/1.73 m² (“abnormal eGFR”) at baseline. The patients who had LVH or low eGFR at baseline were significantly older at symptom onset and diagnosis than those patients with normal LVMI or eGFR at baseline (p < 0.001) [39].

![Fig. 2 Summary of Fabry Outcome Survey data relating to age at onset, diagnosis, and treatment initiation for adults and children. *p < 0.001 vs. earlier period. Data from Reisin et al. [32]](image)
FOS analysis of data from pediatric patients also demonstrated that early treatment with ERT reduced FD symptoms such as pain, vomiting, constipation, and diarrhea at both 12 and 24 months from baseline. In children, baseline renal and cardiac parameters were stable and remained stable with treatment [35]. These FOS analyses together indicate that early, prompt treatment with ERT according to treatment guidelines, before irreversible organ damage has occurred, can help preserve organ function and protect patients from organ damage caused by FD.

**Cardiovascular manifestations**
Analyses of data from FOS have facilitated better understanding of cardiovascular manifestations and long-term cardiovascular outcomes in patients with FD. The high prevalence of cardiovascular morbidity among patients with FD was confirmed in patients enrolled in FOS, with a greater cardiovascular disease burden observed in male patients than in female patients. Cardiovascular manifestations included dyspnea, heart failure, angina, palpitations, arrhythmia, and syncope [46]. A long-term analysis using deconstructed composite events showed that cardiac events occurred at younger ages than renal or cerebrovascular events, and that male patients were more likely than female patients to experience cardiac events at a younger age [36, 38, 47, 48]. In patients treated with agalsidase alfa over 10 years, mean LVMI increased slightly in patients with LVH at baseline, compared with no increases in patients with no LVH at baseline (Table 1) [37, 38].

Another analysis showed that patients treated with agalsidase alfa had a negligible annualized rate of change in LVMI. The mean annual rate of LVMI change was 0.33 g/m²/year in males and 0.48 in females, compared with LVMI increasing at a rate of 4.07 in untreated males and 2.31 in untreated females [35]. Thus, treated patients with LVH at baseline are expected to have a smaller increase in LVMI compared to untreated patients with LVH at baseline, which is a further rationale for prompt treatment with regular follow-up and tests to evaluate disease progression [36]. Furthermore, a recent analysis of FOS data found that LVH present at the start of ERT

| Table 1  | Effect of ERT on clinical outcomes in FOS patients | Publication |
|----------|---------------------------------------------------|-------------|
| Cardiovascular | Mean LVMI increased slightly but significantly over 10 years in patients with LVH at baseline, compared with no increases in patients with no LVH at baseline | Kampmann et al. [37] |
| | LVH was a significantly better predictor of long-term cardiovascular outcomes than normal LVMI in adults at the start of ERT | Ramaswami et al. [38] |
| | Patients with a low eGFR at baseline had a significantly higher risk for a cardiovascular event compared to those with normal eGFR | Feniozzi et al. [39] |
| | Cardiovascular structure and function improved, and renal function stabilized during treatment, although LVMI was only reduced significantly in female patients | Hughes et al. [41] |
| | Composite morbidity events occurred at an older age compared with published findings in untreated patients with FD | Beck et al. [47] |
| Renal | Stabilization of eGFR in female patients | Mehta et al. [26] |
| | 10-year longitudinal data: Reduction in the annual rate of eGFR decline was smaller in treated male patients than expected in untreated patients | Feriozzi et al. [52] |
| | Patients with hyperfiltration (eGFR > 130 mL/min/1.73 m²) at baseline attained an eGFR within the accepted normal range (> 90 mL/min/1.73 m²) with 5 years of starting ERT | Feriozzi et al. [53] |
| | Renal function remained stable in 20 patients with FD who had undergone kidney transplantation and who had received ERT | Ramaswami et al. [38] |
| | Renoprotective effect of ERT is independent of the type of FD mutation | Cybulla et al. [56] |
| Morbidity and Mortality | Most common cause of death shifted from renal disease (pre-2001) to cardiovascular disease (post-2001) | Mehta et al. [48] |
| | Median survival for male ERT-treated patients at 5 years was 17.5 years longer than for untreated male patients | Beck et al. [36] |
| | Probability of a composite morbidity event for ERT vs. placebo was ~16% vs. ~45% | Beck et al. [36] |
| Auditory | Stabilized and/or decreased the progression of hearing loss in FD | Hajioff et al. [62] |
| Gastrointestinal | Prevalence of abdominal pain in male patients and children and prevalence of diarrhea was significantly reduced after 1 year of ERT | Hoffmann et al. [63, 64] |
| Pain | Improved patient pain levels as assessed by the Brief Pain Inventory after 2 years of ERT | Hoffmann et al. [67] |

---

eGFR estimated glomerular filtration rate, ERT enzyme replacement therapy, FD Fabry disease, FOS Fabry Outcome Survey, LVH left ventricular hypertrophy, LVMI left ventricular mass index
was a risk factor for cardiovascular events. Moreover, the subgroup with a low eGFR at baseline also had a significantly higher risk for a cardiovascular event \( (p < 0.001; \) Table 1) \[39\]. A comparison of outcomes after 4 years’ FD treatment with ERT in female patients \( (n = 78) \) and male patients \( (n = 172) \) in FOS found that cardiovascular structure and function improved and renal function stabilized during treatment, although LVMI was only reduced significantly in female patients \( (\text{Table 1}) \) \[41\].

FOS has also enabled the study of cardiovascular events in patients with atypical FD \( (\text{e.g.}, \) patients with \( ISV4 \) mutations) \[9, 10\]. Compared with patients with classic FD, male (but not female) patients with \( ISV4 \) mutations were significantly older when their LVH was initially diagnosed, but no age differences were apparent for other cardiovascular diagnoses \[10\]. Endomyocardial biopsy data for 30 patients with \( ISV4 \) mutations enrolled in FOS showed that a longer duration of ERT was associated with lower Gb3 accumulation and smaller cardiomyocytes, suggesting a possible impact of ERT on the pathophysiology of the disease. The correlation between Gb3 accumulation and LVMI was statistically significant, but moderate, likely because of the small number of biopsies evaluated \[9\]. In addition, retrospective study data showed that there is a reduced risk of thromboembolic events in patients with FD on ERT \[49\].

Uncontrolled hypertension was found to be highly prevalent in FOS \( (57\% \) of male patients, \( 47\% \) of female patients; \( n = 391) \), and both systolic and diastolic blood pressure decreased significantly after 2 years of ERT \[50\]. Hypertension has been linked with decline in renal function in long-term analyses of FOS data \[38, 39\].

Anemia was recorded in 20\% of female patients and 47\% of male patients \( (n = 345) \), and appeared to be associated with decreased eGFR and heart failure—both risk factors for anemia—as well as with inflammation (elevated C-reactive protein). However, although ERT may have positive effects on the cardiovascular manifestations of FD, there is no evidence to date for an effect of ERT on anemia \[51\].

Renal manifestations
Data from FOS have provided much-needed insights into renal function in patients with FD, and the impact of long-term ERT on renal outcomes \( (\text{Table 1}) \). An analysis of FOS data from 366 patients with FD revealed that, prior to ERT start, 50\% of patients reported renal events \( (\text{i.e., proteinuria, dialysis, end-stage renal disease, or renal transplant}) \[12\]. The benefit of long-term ERT for up to 10 years in patients with FD-related nephropathy, where baseline eGFR was \( \geq 30 \text{ ml/min/1.73 m}^2 \), was later confirmed using FOS data, with stabilization of eGFR achieved in female patients, and a reduction in the annual rate of eGFR decline in male patients \( (\text{Table 1}) \) \[26, 38, 52, 53\]. After 5 years of treatment with ERT, 12 of 14 patients \( (86\%) \) who had hyperfiltration \( (\text{eGFR} > 130 \text{ mL/min/1.73 m}^2) \) at baseline attained an eGFR within the accepted normal range \( (> 90 \text{ mL/min/1.73 m}^2) \) \[26\]. Additionally, in long-term analyses with up to 10 years’ follow-up, baseline proteinuria > 1 g/24 h was found to have a negative influence on renal function over time \[38, 39\]. Twelve-year data from additional long-term analyses of male FOS patients found that ERT with agalsidase alfa may be associated with potential renoprotective effects, leading to the stabilization of renal function relative to the expected decline in patients with FD \[40, 54, 55\]. A greater annual rate of change in proteinuria was observed in a group of patients with FD, including patients previously receiving angiotensin receptor blockers or angiotensin-converting enzyme inhibitors, and high renal involvement \( (\text{proteinuria} > 0.5 \text{ g/24 h}) \) at baseline versus a group of patients with FD and low renal involvement \( (\text{proteinuria} \leq 0.5 \text{ g/24 h}) \) at baseline, confirming the role of proteinuria as a risk factor for renal impairment \[38, 40, 54, 55\]. These observations should be considered in the context of the natural history of FD as described in the literature. A retrospective chart review of 279 male untreated patients examined between 1944 and 2002, with only approximately one-third of these patients receiving angiotensin receptor blockers or angiotensin-converting enzyme inhibitors, showed more rapid loss of renal function with proteinuria at baseline \[38\]. Renal function remained stable in 20 patients with FD who had undergone kidney transplantation and who had received agalsidase alfa; however, further data are required to evaluate the long-term renoprotective effects of ERT following transplantation \( (\text{Table 1}) \) \[55, 56\].

Long-term FOS data confirmed an association between renal and cardiovascular outcomes, with greater declines in renal function over time apparent in patients with baseline arterial hypertension compared with those without \[38, 39, 53\], and greater overall risk of experiencing a cardiovascular event in patients with poor renal function at baseline compared with patients with eGFR at or near the reference range \[39\]. Ultimately, FOS data suggest that ERT should be administered at an early stage of disease to reduce FD progression and protect patients from organ damage.

Cerebrovascular manifestations
The incidence and prevalence of cerebrovascular events in patients with FD were identified in FOS studies for male versus female patients and classic versus atypical FD phenotype. Cerebrovascular events (primarily transient ischemic attacks and ischemic strokes) are an important
cause of morbidity and mortality in patients with FD, although incidence rates vary. Cerebrovascular events occurred in 11.1–25% of male patients and 15.7–21% of female patients enrolled in FOS [48, 57], although male patients experienced these events at a younger age than female patients (mean 39.2 and 51.4 years, respectively) [48]. The number of ischemic lesions found on brain magnetic resonance imaging was similar in classic and atypical (pSV4 mutation) FD and much higher than in the general population, with some differences in location in a study of FOS participants in Taiwan [58]. While the evidence to support a direct effect of ERT on cerebrovascular events is still controversial, the likelihood of indirect effects due to improved cardiovascular and renal function has been suggested [57].

**Ocular, auditory, gastrointestinal, and dermatologic manifestations**

FOS analyses have shown that ocular, auditory, gastrointestinal, and dermatologic manifestations of FD may be important signs of disease severity and can affect patient QoL. The most common ocular signs of FD in FOS were cornea verticillata, tortuous conjunctival/retinal vessels, and posterior spoke-like cataracts [59, 60]. The high prevalence of ocular signs and symptoms in children, affecting 54.5% of girls (n = 101) and 47.3% of boys (n = 131) with FD, suggests they could be a valuable diagnostic tool in this age group. Children and adults with ocular findings also had higher median age—adjusted FOS-MSSI scores than those without, suggestive of an association with more severe FD in children and adults [59, 61]. The prevalence of cornea verticillata was also significantly higher in patients with null or missense GLA mutations, compared with those with the p. N215S or mild missense mutations [61].

FOS studies have shown that ERT can stabilize and/or decrease the progression of hearing loss in FD. Analysis of FOS data determined that although there were no changes in patients with normal hearing or with severe hearing loss at baseline, hearing thresholds improved significantly by 4–7 dB across most frequencies for those with mild or moderate hearing loss at baseline, suggesting that agalsidase alfa can stabilize or possibly improve hearing in this small number of patients who have not progressed to severe hearing loss, however further studies are required [62].

FOS analyses have shown that ERT can improve gastrointestinal symptoms in patients with FD. Among the patients enrolled in FOS (n = 342), gastrointestinal symptoms were reported for 54.2% of females and 48.9% of males, and included abdominal pain (32.5%), diarrhea (20.5%), constipation (13.5%), and nausea (12.3%) and vomiting (6.7%) [63, 64]. Abdominal pain was present in 49.3% of children and, like diarrhea, was more frequent in children than adults [35, 63, 64]. After 1 year of ERT, the prevalence of abdominal pain in male patients and children was significantly reduced, as was the prevalence of diarrhea in children, with no child reporting diarrhea as a new symptom; results were similar after 2 years (Table 1) [63, 64].

Dermatologic manifestations are common in FD and were found in 78% of male patients and 50% of female patients in an analysis of early FOS data [12]. Among patients enrolled in FOS, angiookeratomas were the most common dermatologic manifestation and occurred more frequently (66% vs. 36%) and at a younger age (mean 17.9 vs. 29.1 years) in male versus female patients [12, 65]. Hypohidrosis was the next most common dermatologic symptom, occurring in 53% of male patients and 28% of female patients [65], whereas hyperhidrosis, although less common overall, was more prevalent in female patients (11.9%; n = 369) than male patients (6.4%; n = 345) with FD [66]. The presence of cutaneous vascular lesions in the skin was associated with more severe FD with major organ involvement; however, there is no clear evidence to support an effect of ERT on skin lesions [65] or other dermatologic issues [66].

**Pain and QoL**

FOS has improved the understanding of how FD affects patient QoL. An analysis of a cohort of 120 FOS patients from the United Kingdom found that baseline health-related QoL scores (EuroQol 5 Dimension [EQ-5D] utility scores) were significantly below those of the general UK population, with no differences between male and female patients; however, significant improvements in QoL were achieved after 1 year of ERT, reaching scores similar to the general population [67]. Improvements in QoL were maintained after 5 years of ERT [26]. A key factor in the improvement in health-related QoL scores was change in the EQ-5D pain-related dimension score, underlining the impact of pain on QoL in FD [26, 67]. In addition to the QoL findings, a separate analysis found that following 2 and 5 years of ERT, patients in FOS reported that their pain had improved significantly from baseline as assessed by the Brief Pain Inventory (Table 1) [26, 67].

**Morbidity, mortality and causes of death**

The availability of ERT, beginning in 2001, has brought about changes in the natural course of FD, not least an impact on life expectancy and causes of death. Among both male and female patients enrolled in FOS who received ERT, the most common cause of death was cardiovascular disease (34% of male patients and 57% of female patients) [48]. In contrast, the majority of deaths
that in patients starting ERT in childhood or early adulthood, renal and/or cardiac disease progression was attenuated compared with adults > 30 years old [45]. For the 151 patients who were ≤ 18 years of age, mean annual rates of change in eGFR, proteinuria, and LVMI were stable and remained stable with agalsidase alfa treatment. However, patients who were > 18 years to < 30 years of age showed significant yearly deterioration in eGFR over the follow-up period (p < 0.001), and patients > 30 years of age showed significant yearly deterioration in eGFR, proteinuria, and LVMI (p < 0.001 for each), suggesting the value of initiating treatment early to protect from end-organ damage and attenuate disease progression [45].

Three FOS publications have specifically described FD in female patients. Among 303 female patients enrolled in FOS, the most common symptoms were neurologic (77%) and cardiovascular (59%), with renal signs and symptoms present in 40% [70]. Neurologic features appeared at a mean age of 16 years, cardiac features at 34 years, and renal involvement at 37 years. FOS data identified geographic differences in disease severity among female patients with FD, with female patients in northern European countries having significantly higher FOS-MSSI scores, representing more severe disease, than those living in southern European countries, although the extra-genetic or epigenetic (e.g., dietary) factors involved have not been identified [71]. These results, however, should be interpreted with caution because it is possible that the awareness or interpretation of disease (i.e., pain) in female patients differs in northern and southern European countries. A FOS analysis of reproductive and pregnancy-related outcomes showed that age at menarche and age at menopause were similar between never-treated female patients with FD and agalsidase alfa–treated female patients with FD [72]. Among those female patients with FD who completed a pregnancy questionnaire, 91.3% of 23 pregnancies in 21 female patients treated with agalsidase alfa versus 96% of female patients treated with agalsidase alfa–treated female patients with FD [72]. Further, no significant differences in any of the tested renal and cardiac parameters were observed after pregnancy, regardless of treatment status [72].

A limited number of analyses have been conducted on outcomes in elderly patients in FOS. A 2016 analysis of elderly patients in FOS showed that although FOS patients aged ≥ 75 years had more severe cardiomyopathy and a higher prevalence of hypertension, and lower eGFR than those aged 18–49 years, a smaller proportion were being treated (50% vs. 64.6%). It was suggested that this could be due to a relatively milder disease burden in the older age group or to patient and/or physician...
FOS findings in line with other real-world data

Data from FOS are further supported by findings from the Fabry Registry, a global observational research platform for FD, where most patients who died from FD were reported to have serious cardiac and renal dysfunction [75]. Furthermore, cardiovascular events were reported in more male than female patients [76] and were the most common type of initial clinical presentation in male and female with FD in Latin America [77]. Findings from this registry showed that initiation of ERT at a younger age reduced the risk for cardiovascular events [78] and/or renal dysfunction [79, 80]. However, despite ERT, patients with advanced FD continued to be at risk for serious cardiac or renal events [81–85]. Other country-specific registries also provided broadly similar data to FOS [86–90].

Key learnings and challenges

Since its inception, FOS has contributed significantly to the understanding of FD, including the effects of ERT on late-onset versus classic FD. Further, ongoing analyses of FOS data have highlighted the changing landscape of FD over time. FOS publications have putatively increased physicians’ awareness of FD and perhaps thereby shortened delays in diagnosis. An update of the analysis of delays between symptom onset and diagnosis in FD is warranted. Additionally, analyses of biomarkers, documented mutations, genotype-phenotype, cerebrovascular events in FD and the impact of ERT on outcomes in elderly patients are still being considered for the future. However, several challenges have been encountered throughout the duration of FOS, many of which are related to the nature of registries, although others are specific to FOS. The quality of registry data observed in FOS is determined—and limited—by the quantity and quality of the information inputted by participating physicians. As data are collected during routine clinical practice, with variation in both the frequency of visits and the assessments carried out at each visit, data may be incomplete, resulting in low patient numbers for certain parameters and subgroups. Further improvements in data completeness by focusing on core variables are therefore vital. The most notable missing data in FOS are for genotype, owing to changes in patient informed consent documentation for these data. Also, baseline characteristics of treated and untreated patients in FOS are not comparable, as mildly affected untreated patients are switched to treatment as their disease becomes more severe, and therefore there is a need to use a historical comparator group instead of an internal comparator group in certain FOS analyses, which also creates challenges in interpreting results. Differences in diagnostic and treatment practices among regions and countries have also been a challenge with FOS.

Looking to the future

Because FD is a chronic condition, patients may require long-term treatment throughout adulthood beyond the parameters studied previously. Findings from FD registries may be used to inform treatment guidelines, including establishing the ideal timing of treatment initiation, identifying novel biomarkers for better disease management, or helping to formulate management recommendations. Real-world data suggesting that female patients with FD may be under-treated [42] could support changes in medical practice that ensure female patients with FD receive ERT when appropriate. Future studies with larger sample sizes would be valuable to better understand atypical FD subtypes, such as those described for the mutations IVS4 and p.Ala143Thr [8–10, 58]. As further developments are made in the diagnosis and management of patients with FD, FOS and other FD registries will need to be adapted to ensure they capture the most relevant data. For example, the addition of a free-text field in the FOS database would enable the collection of data regarding the effectiveness of new treatments or information regarding signs and symptoms that have not yet been observed or described. Patient-reported outcomes are increasingly recognized for their value in patient management, and more emphasis on these measures in future studies is needed. In the future, new technologies could enable faster, more efficient data aggregation from electronic medical records, as well as from other sources such as smartphone app-based patient-reported outcome questionnaires or mobile data-logging devices. More powerful data processing and artificial intelligence systems could potentially enable the extraction of uniform data for a particular parameter that may have originally been recorded in different formats. These efforts would aid data aggregation and analysis by making data more searchable, accessible, and extractable. In addition, as technology allows healthcare to become more patient centric, patients are increasingly keen to maintain control over their personal data. Development of blockchain technology may allow increased security, privacy, and interoperability of health data. This technology could provide a new model for health information exchanges by making electronic medical records more efficient and disintermediated. Future registry analyses in
FD should explore the lifetime impact of ERT in specific populations (e.g., patients receiving a kidney transplant), seek to develop better tools and biomarkers for diagnosis and the determination of FD severity, and further characterize FD mutations and their relationship with specific disease phenotypes. Ongoing efforts to better understand the natural history and symptoms of atypical FD subtypes are essential.

Conclusions
The data collected in FOS over the last 20 years have increased our understanding of the natural history of FD. FOS analyses have contributed to the body of FD knowledge by evaluating the long-term effectiveness and safety of ERT with agalsidase alfa and the impact of ERT not only on survival but also on the cardiovascular and renal manifestations of FD. FOS analyses have also provided better understanding of the specific issues faced by women, children, and elderly patients with FD, and have provided practical tools for the study of FD.

Abbreviations
α-Gal A: α-Galactosidase A; eGFR: Estimated glomerular filtration rate; EQ-SD: EuroQol 5 Dimension; ERT: Enzyme replacement therapy; FD: Fabry disease; FIP1: Fabry International Prognostic Index; FIRE: Fabry International Research Exchange; FOS: Fabry Outcome Survey; FOS-MSSI: FOS Mainz Severity Score Index; FHPIQC: Fabry-specific Pediatric Health and Pain Questionnaire; Gb3: Globotriaosylceramide; GLA: Galactosidase alpha; HR: Hazard ratio; LVH: Left ventricular hypertrophy; LVMI: Left ventricular mass index; MSSI: Mainz Severity Score Index; QoL: Quality of life.

Acknowledgements
The authors would like to thank the patients enrolled in FOS, their caregivers, and the FOS physicians and their staff. The authors would also like to thank previous members of the FOS Steering Committee and the investigators involved in previous FOS publications. Under the direction of the authors, Latoya M. Mitchell, PhD, CMPP and Lindsay Napier, PhD, CMPP, employees of Excel Medical Affairs, provided writing assistance for this publication. Editorial assistance in formatting, proofreading, copy editing, and fact-checking was also provided by Excel Medical Affairs.

Author contributions
MB, UR, RH-S, DAH, CK, ABM, KN, D-MN, GP-M, RR, MLW, JS, CA, JB, and RG each provided substantial contributions to the design of the review and the interpretation of literature for the work; were involved in drafting the work or revising it critically for important intellectual content; approved the final version to be published; and have agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors read and approved the final manuscript.

Funding
FOS is funded by Takeda Pharmaceuticals International AG, which also assisted in analyzing the data and preparing the manuscript. Takeda Development Center Americas, Inc. provided funding to Excel Medical Affairs for support in writing and editing this manuscript.

Availability of data and materials
The datasets, including the redacted study protocol, redacted statistical analysis plan, and individual participants’ data supporting the results reported in this article will be provided after its de-identification, in compliance with applicable privacy laws, data protection, and requirements for consent and anonymization.

Declarations

Ethics approval and consent to participate
FOS was approved by the ethics institutional review boards of participating centers. Further, this registry was compliant with relevant global and local regulations and best practices: Good Pharmacopoeidemological Practice, Good Research for Comparative Effectiveness principles, and the relevant principles of the International Conference on Harmonisation Good Clinical Practice guidelines were followed as appropriate for an observational registry, consistent with the Declaration of Helsinki.

Consent for publication
Patient consent for publication was not required.

Competing interests
MB reports honoraria for speaking and/or advisory boards from Sanofi Genzyme and Takeda. He is a member of the FOS Steering Committee. UR reports honoraria for speaking and/or advisory boards from Amicus Therapeutics, Sanofi Genzyme, and Takeda, and research grants from Amicus Therapeutics and Takeda. She is a member of the FOS Steering Committee. EH-S reports no conflict of interest. DAH reports honoraria from Amicus Therapeutics, Freeline Therapeutics, Idorsia, Protalix, Sanofi Genzyme, and Takeda. She is a member of the FOS Steering Committee. CK reports honoraria for speaking and/or advisory boards from Amicus, BioMarin, Genentech, and Takeda. He is a member of the FOS Steering Committee. ABM reports honoraria from Amicus Therapeutics, Aventis, Freeline Therapeutics, Protalix, Sanofi Genzyme, and Takeda. He is a former member of the FOS Steering Committee and past chair of the FOS Steering Committee. KN reports honoraria from Amicus Therapeutics, Sanofi Genzyme, and Takeda. She is a member of the FOS Steering Committee. D-MN reports honoraria and speaker fees from Sanofi Genzyme and Takeda, and research grants from BioMarin, Sanofi Genzyme, and Takeda. He is a member of the FOS Steering Committee. GP-M reports honoraria from Alexion, Amicus, BioMarin, Sanofi Genzyme, and Takeda, and unrestricted grants from Sanofi Genzyme and Takeda to the Vall d’Hebron Research Foundation for funding research on rare diseases. He is a member of the FOS Steering Committee. RR reports honoraria, speaker fees, and consulting fees from Amicus Therapeutics, CSL Behring, Genzyme, and Takeda. He is a member of the FOS Steering Committee. MLW reports grants, personal fees, and travel support from Amicus Therapeutics, Idorsia, Protalix, Sanofi Genzyme, and Takeda. He is a member of the FOS Steering Committee. JS is an employee of Takeda Pharmaceuticals Company Limited and a stockholder of Takeda Pharmaceuticals Company International AG. He is an employee of Takeda Pharmaceuticals Company Limited. JB is an employee of Takeda Pharmaceuticals Company International AG and is also a stockholder of Takeda Pharmaceuticals Company Limited. RG reports honoraria, consulting fees, speaker fees, research funding, and/or travel reimbursement from Abeona, Allievex, Amicus Therapeutics, Aventis, BioMarin, Chiesi, Denali Therapeutics, Idorsia, Inventiva, Janssen, JCR Pharmaceuticals, Lysogene, Novartis, Paradigm Biopharma, Passage Bio, Protalix, PTC Therapeutics, Regenshio, Sanofi Genzyme, Sobi, Takeda, and ultrasound. He is a member and current chair of the FOS Steering Committee.

Author details
1 SphinCS GmbH, Institute of Clinical Science LSD, Hochheim, Germany. 2 Lyssonol Disorders Unit, Institute of Immunity and Transplantation, Royal Free London NHS Foundation Trust, University College London, London, UK. 3 Late Phase Solutions Europe AB, Täby, Sweden. 4 Johannes Gutenberg School of Medicine, University of Mainz, Mainz, Germany. 5 Department of Haematology, University College London, London, UK. 6 Department of Haematology, University College London, London, UK. 7 The Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia. 8 Taipei Veterans General Hospital, Taipei, Taiwan. 9 Reference Centre for Hereditary Metabolic Disorders (MetabERN), Vall d’Hebron University Hospital, Barcelona, Spain. 10 Hospital Británico de Buenos Aires, Buenos Aires, Argentina. 11 Department of Medicine, Dalhousie University, Halifax, NS, Canada. 12 Takeda Pharmaceuticals International AG, Zurich, Switzerland. 13 Takeda Pharmaceuticals International AG, Zurich, Switzerland. 14 Department of Genetics, UFRGS, Medical Genetics Service, HCPA, Porto Alegre, Brazil.
References

1. Potter BK, Khangura SD, Tingley K, Chakraborty P, Little J. Translating rare-disease therapies into improved care for patients and families: what are the right outcomes, designs, and engagement approaches in health-systems research? Genet Med. 2016;18(2):117–23.

2. Clarke JT, Gugliani R, Sunder-Plassmann G, Elliot PM, Pintos-Morell G, Hemmings-Stähl E, et al. FOS investigators. Impact of measures to enhance the value of observational surveys in rare diseases: the Fabry Outcome Survey (FOS). Value Health. 2011;14(6):862–6.

3. Hemberg-Stahl E. Organization and technical aspects of FOS: the Fabry Outcome Survey. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis; 2006.

4. Gugliani R, Niu D-M, Ramaswami U, West M, Hughes H, Kampmann C, et al. A 15-year perspective of the Fabry Outcome Survey. J Inborn Errors Metab Screen. 2016;4:232640981666298. https://doi.org/10.1177/232640981666298.

5. Brady RO, Gal AE, Bradley RM, Martensson E, Warnshaw AL, Laster L. Enzyme defect in Fabry's disease: Ceramidetrihexosidase deficiency. N Engl J Med. 1967;276(21):1163–7.

6. Mehta A, Beck M, Linhart A, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis; 2006.

7. Eng CM, Niehaus DJ, Enriquez AL, Burgert TS, Ludman MD, Desnick RJ. Fabry disease: twenty-three mutations including sense and antisense CpG alterations and identification of a deletional hot-spot in the alpha-galactosidase A gene. Hum Mol Genet. 1994;3(10):1795–9.

8. Teryn W, Vanholder R, Hemelsoot D, Leroy BP, Van Biesen W, De Schoenmaker G, et al. Questioning the pathogenic role of GLA p.A641Thr "mutation" in Fabry disease: implications for screening studies and ERT. JIMD Rep. 2013;8:101–8.

9. Hsu TR, Chang FP, Chu TH, Sung SH, Bzijaveja S, Yu WC, et al. Correlations between endomyocardial biopsies and cardiac manifestations in Taiwanese patients with the Chinese hotspots IVS4+919G>A mutation: data from the Fabry Outcome Survey. Int J Mol Sci. 2017;18(1):119.

10. Liu HC, Perrin A, Hsu TR, Yang CF, Lin HY, Yu WC, et al. Age at first cardiac symptoms in Fabry disease: association with a Chinese hotspot Fabry mutation (IVS4+919G>A), classical Fabry mutations, and sex in a Taiwanese population from the Fabry Outcome Survey (FOS). JIMD Rep. 2015;22:107–13.

11. Stenson PD, Mort M, Ball EV, Evans K, Hayden M, Heywood S, et al. The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Hum Genet. 2017;136(6):665–77.

12. Mehta A, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004;34(3):236–42.

13. MacDermot KD, Holmes A, Miners AH. Anderson–Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis; 2006.

14. Mehta A, Beck M, Linhart A, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis; 2006.

15. Spada M, Bahrör S, Yang CG, Lin HY, Yu WC, et al. Age at first cardiac symptoms in Fabry disease: association with a Chinese hotspot Fabry mutation (IVS4+919G>A), classical Fabry mutations, and sex in a Taiwanese population from the Fabry Outcome Survey (FOS). JIMD Rep. 2015;22:107–13.

16. Mehta A, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004;34(3):236–42.

17. MacDermot KD, Holmes A, Miners AH. Anderson–Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis; 2006.

18. Mehta A, Perrin A, Bahrör S, Yang CG, Lin HY, Yu WC, et al. Age at first cardiac symptoms in Fabry disease: association with a Chinese hotspot Fabry mutation (IVS4+919G>A), classical Fabry mutations, and sex in a Taiwanese population from the Fabry Outcome Survey (FOS). JIMD Rep. 2015;22:107–13.

19. Beck M, Cox TM. Comment: why are females with Fabry disease affected? Mol Genet Metab Rep. 2019;21:100529.

20. Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, et al. European expert consensus statement on therapeutic goals in Fabry disease. Mol Genet Metab. 2018;124(3):189–203.

21. Schifferman R, Brady RO. Development of enzyme replacement therapy for Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis; 2006.

22. Shire Human Genetic Therapies. REPLAGAL (agalsidase alfa) 1 mg/ml concentrate for solution for infusion. Prescribing information for great Britain. https://www.takeda.com/4ad84ff/siteassets/en-gb/home/hcpqs/replagal_pi.pdf. Accessed 20 January 2021.

23. Genzyme. FABRAZYME® (agalsidase beta for injection). Prescribing information. 2021. http://www.abavis.com/assets/npd_info3_eng.pdf. Accessed 10 December 2021.

24. Amicus. GALAFOLD® (migalastat) capsules, for oral use. Prescribing information. 2018. https://www.amicusrx.com/pi/galafold.pdf. Accessed 20 January 2021.

25. Mehta A, Beck M, Elliot P, Gugliani R, Linhart A, Sunder-Plassmann G, et al. Fabry Outcome Survey investigators. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet. 2009;374(9696):1086–96.

26. Hughes DA, Ramaswami U, Barba Romero M, Deegan P, FOS investigators. Age adjusting severity scores for Anderson–Fabry disease. Mol Genet Metab. 2010;101(2–3):219–27.

27. Whybra C, Kampmann C, Krummennauer F, Ries M, Mangel E, Miebach E, et al. The Mainz Severity Score Index: a new instrument for quantifying the Anderson–Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet. 2004;65(4):299–307.

28. Hughes DA, Malmenäs M, Deegan PB, Elliot PM, Ginsberg J, Hajjof D, et al. FOS investigators. Fabry International Prognostic Index: a predictive severity score for Anderson–Fabry disease. J Med Genet. 2012;49(3):212–20.

29. Ramaswami U, Stull DE, Parini R, Pintos-Morell G, Whybra C, Kalkum G, et al. FOS investigators. Measuring patient experiences in Fabry disease: validation of the Fabry-specific Pediatric Health and Pain Questionnaire (FHPQ). Health Qual Life Outcomes. 2012;10:116.

30. Whybra C, Bahrör F, Baron K. Measurement of disease severity and progression in Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis; 2006.

31. Reisin R, Perrin A, García-Pavía P, Pertsemlidis A, Kalkum G, et al. FOS investigators. Anderson–Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis; 2006.

32. Reisin R, Perrin A, García-Pavía P. Time delays in the diagnosis and treat ment of Fabry disease. Int J Clin Pract. 2017;71(11):12914.

33. Schaefer E, Mehta A, Gal A. Genotype and phenotype in Fabry disease: analysis of the Fabry Outcome Survey. Acta Paediatr Suppl. 2005;94(447):87–92 (discussion 79).

34. Ramaswami U, Parini R, Kampmann C, Beck M. Safety of agalsidase alfa in patients with Fabry disease under 7 years. Acta Paediatr. 2011;100(4):605–11.

35. Ramaswami U, Parini R, Pintos-Morell G, Kalkum G, Kampmann C, Beck M. FOS investigators. Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey. Clin Genet. 2012;81(5):485–90.

36. Beck M, Hughes D, Kampmann C, Laroque S, Mehta A, Pintos-Morell G, et al. Fabry Outcome Survey Study Group. Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: a Fabry Outcome Survey analysis. Mol Genet Metab Rep. 2015;3:21–7.

37. Kampmann C, Perrin A, Beck M. Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment. Orphanet J Rare Dis. 2015;10:125.

38. Ramaswami U, Beck M, Hughes D, Kampmann C, Botha J, Pintos-Morell G, et al. FOS Study Group. Cardio-renal outcomes with long-term agalsidase alfa enzyme replacement therapy: a 10-year Fabry Outcome Survey (FOS) analysis. Drug Des Devel Ther. 2019;13:3705–15.

39. Feriozzi S, Linhart A, Ramaswami U, Kalampani V, Gurevich A, Hughes D. Fabry Outcome Survey Study Group. Effects of baseline left ventricular
hypertrophy and decreased renal function on cardiovascular and renal outcomes in patients with Fabry disease treated with agalsidase alfa: a Fabry Outcome Survey study. Clin Ther. 2020;42(12):2531–30.

40. Cybulla M, Nicholls K, Ferriozzi S, Torres J, Vukovac B, Gurevich A, et al. Renoprotective effect of agalsidase alfa in Fabry disease is independent of type of mutation: results of 12-year follow-up. Nephrol Dial Transplant. 2019;34(Suppl 1):gzt106.P144.

41. Hughes DA, Barba Romero M, Hollak CE, Giugliani R, Deegan PB. Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS—the Fabry Outcome Survey. Mol Genet Metab. 2011;103(3):207–14.

42. Barba-Romero MA, Pintos-Morell G. Gender differences in the application of Spanish criteria for initiation of enzyme replacement therapy for Fabry disease in the Fabry Outcome Survey. Int J Mol Sci. 2016;17(12):1965.

43. Lenders M, Hennermann JB, Kurschat C, Rolfs A, Canaan-Kühle S, Sommer C, et al. Multicenter Female Fabry Study (MFFS): clinical survey on current treatment of females with Fabry disease. Orphanet J Rare Dis. 2016;11(1):88.

44. Hughes D, Linhart A, Gurevich A, Kalampoki V, Jazouliene V, Ferriozzi S, et al. FOS Study Group. Prompt agalsidase alfa therapy initiation is associated with improved renal and cardiovascular outcomes in a Fabry Outcome Survey analysis. Drug Des Devel Ther. 2021;15:3561–72.

45. Parini R, Pintos-Morell G, Hennermann JB, Hsu TR, Karabul N, Kalampoki V, et al. FOS Study Group. Analysis of renal and cardiovascular outcomes in male participants in the Fabry Outcome Survey starting agalsidase alfa enzyme replacement therapy before and after 18 years of age. Drug Des Devel Ther. 2020;14:2149–58.

46. Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A, et al. European FOS Investigators. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry Outcome Survey. Eur Heart J. 2007;28(10):1228–35.

47. Beck M, Hughes D, Kampmann C, Pintos-Morell G, Ramaswami U, West ML, et al. Long-term outcomes with agalsidase alfa enzyme replacement therapy: analysis using deconstructed composite events. Mol Genet Metab Rep. 2018;14:31–5.

48. Pintos-Morell G, Hennermann JB, Hsu TR, Karabul N, Kalampoki V, et al. FOS Study Group. Natural course of Fabry disease: changing pattern of causes of death in FOS—Fabry Outcome Survey. J Med Genet. 2009;46(8):548–52.

49. Lenders M, Karabul N, Duning T, Schmitz B, Schellekens M, Mesters R, et al. Thromboembolic events in Fabry disease and the impact of factor V Leiden. Neurology. 2013;84(10):1009–16.

50. Kleinert J, Dehouf F, Schwarting A, de Lorenzo AG, Ricci R, Kampmann C, et al. Prevalence of uncontrolled hypertension in patients with Fabry disease. Am J Hypertens. 2006;19(8):782–7.

51. Kleinert J, Dehouf F, Schwarting A, de Lorenzo AG, Ricci R, Kampmann C, et al. The impact of factor V Leiden on the decline in renal function in patients with Fabry disease. Am J Nephrol. 2009;29(5):353–61.

52. Ferriozzi S, Torres J, Cybulla M, Nicholls K, Sunder-Plassmann G, West M, FOS investigators. The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy. Clin J Am Soc Nephrol. 2012;7(11):69–9.

53. Nicholls K, West M, Gurevich A, Botra J, Cybulla M. Renoprotective effect of agalsidase alfa. 12-year follow-up of Fabry patients. Kidney Int Rep. 2019;4(7 Suppl):S239.

54. West M, Cybulla M, Nicholls K, Ferriozzi S, Torres J, Vukovac B, et al. Renoprotective effect of agalsidase alfa: 12-year follow-up of male Fabry patients. Mol Genet Metab. 2019;126(2):51.

55. Cybulla M, Walter KN, Schwarting A, Divito R, Ferriozzi S, Sunder-Plassmann G, European FOS Investigators Group. Kidney transplantation in patients with Fabry disease. Transpl Int. 2009;22(4):475–81.

56. Mehta A, Ginsberg L. FOS Investigators. Natural history of the cerebrovascular complications of Fabry disease. Acta Paediatr Suppl. 2005;494(47):24–7 (discussion 9–10).

57. Lee HJ, Hsu TR, Hwang SC, Wu WC, Chu TH, Yang CF, et al. A comparison of central nervous system involvement in patients with classical Fabry disease or the later-onset subtype with the V544A 919G>A mutation. BMC Neuro. 2017;17(1):25.

58. Kalkum G, Pitz S, Karabul N, Beck M, Pintos-Morell G, Parini R, et al. Paediatric Fabry disease: prognostic significance of ocular changes for disease severity. BMC Ophthalmol. 2016;16(1):202.

59. Sodi A, Ioannidis AS, Mehta A, Davey C, Beck M, Pitz S. Ocular manifestations of Fabry’s disease: data from the Fabry Outcome Survey. Br J Ophthalmol. 2007;91(2):210–4.

60. Pitz S, Kalkum G, Arash L, Karabul N, Sodi A, Larroque S, et al. Ocular signs correlate well with disease severity and genotype in Fabry disease. PLOS ONE. 2015;10(3):e0120814.

61. Hajoef D, Hegemann S, Conti G, Beck M, Sunder-Plassmann G, Widmer U, et al. Agalsidase alfa and hearing in Fabry disease: data from the Fabry Outcome Survey. Eur J Clin Invest. 2006;36(9):663–7.

62. Hoffmann B, Keshav S. Gastrointestinal symptoms in Fabry disease: everything is possible, including treatment. Acta Paediatr. 2007;96(455):84–6.

63. Hoffmann B, Schwarz M, Mehta A, Keshav S. Fabry Outcome Survey European Investigators. Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol. 2007;5(12):1447–53.

64. Orteu CH, Jansen T, Lidove O, Jaussaud R, Hughes DA, Pintos-Morell G, et al. FOS Investigators. Fabry disease and the skin: data from FOS, the Fabry Outcome Survey. Br J Dermatol. 2007;157(2):331–7.

65. Lidove O, Ramaswami U, Jaussaud R, Barbe F, Maisonneuve T, Caillaud C, et al. FOS European Investigators. Hyperhidrosis: a new and often early symptom in Fabry patients. Orphanet J Rare Dis. 2006;1:25.

66. Beck M, Ramaswami U, Hughes D, Kampmann C, Nicholls K, Niu D-M, et al. FOS Outcome Survey. Orphanet J Rare Dis. 2019;34(Suppl 1):gfz106.FP14.
Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry. Mol Genet Metab. 2016;119(1–2):151–9.

81. Rombach SM, Hollak CE, Linthorst GE, Dijkgraaf MG. Cost-effectiveness of enzyme replacement therapy for Fabry disease. Orphanet J Rare Dis. 2013;8:29.

82. Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MG, Hollak CE. Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis. 2013;8:47.

83. Warnock DG, Ortiz A, Mauer M, Linthorst GE, Oliveira JP, Serra AL, et al. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transpl. 2012;27(3):1042–9.

84. Weidemann F, Niemann M, Störk S, Breunig F, Beer M, Sommer C, et al. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med. 2013;274(4):331–41.

85. Wyatt K, Henley W, Anderson L, Anderson R, Nikolaou V, Stein K, et al. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders. Health Technol Assess. 2012;16(39):1–543.

86. Borgwardt L, Feldt-Rasmussen U, Rasmussen AK, Ballegaard M, Meldgaard LA. Fabry disease in children: agalsidase-beta enzyme replacement therapy. Clin Genet. 2013;83(5):432–8.

87. Madsen CV, Granqvist H, Petersen JH, Rasmussen AK, Lund AM, Oturai P, et al. Age-related renal function decline in Fabry disease patients on enzyme replacement therapy: a longitudinal cohort study. Nephrol Dial Transplant. 2019;34(9):1525–33.

88. Mauhni W, Benveniste O, Amelin D, Montagner C, Lamari F, Caillaud C, et al. Cornea verticillata and acroparesthesia efficiently discriminate clusters of severity in Fabry disease. PLOS ONE. 2020;15(5):e0233460.

89. Yazdanfard PD, Madsen CV, Nielsen LH, Rasmussen AK, Petersen JH, Seth A, et al. Significant hearing loss in Fabry disease: study of the Danish nationwide cohort prior to treatment. PLOS ONE. 2019;14(12): e0225071.

90. Yazdanfard PDW, Effraimidis G, Madsen CV, Nielsen LH, Rasmussen AK, Petersen JH, et al. Hearing loss in fabry disease: A 16 year follow-up study of the Danish nationwide cohort. Mol Genet Metab Rep. 2022;31: 100841.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.